Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 2-Part, Randomized, Double-Blind, Placebo-Controlled Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping With an Initial Multiple Ascending Dose Part A to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ENTR-601-44, Followed by Part B to Evaluate the Safety and Efficacy of ENTR-601-44 (ELEVATE-44)

NCT07037862 is registered in ClinicalTrials.gov with Entrada Therapeutics, Inc. as lead sponsor.

NCT NCT07037862
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07037862 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 2-Part, Randomized, Double-Blind, Placebo-Controlled Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping With an Initial Multiple Ascending Dose Part A to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ENTR-601-44, Followed by Part B to Evaluate the Safety and Efficacy of ENTR-601-44 (ELEVATE-44)
Lead sponsor
Entrada Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 30, 2025
Completion date
March 28, 2029
Enrollment
24 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

duchenne muscular dystrophy (dmd)